Population In Vitro-In Vivo Correlation Model for Pramipexole Slow-Release Oral Formulations

2009 ◽  
Vol 27 (2) ◽  
pp. 340-349 ◽  
Author(s):  
Elena Soto ◽  
Sebastian Haertter ◽  
Michael Koenen-Bergmann ◽  
Alexander Staab ◽  
Iñaki F. Trocóniz
Keyword(s):  
Slow Release ◽  
Correlation Model ◽  
Oral Formulations

Development and Validation of an In Vitro and In Vivo Correlation Model in NZ Rabbit for Topiramate Extended Release Capsules

2016 ◽  
Vol 78 (6) ◽  
Author(s):  
T S Laxman ◽  
Y Durgaprasad ◽  
H K Tirgar ◽  
H Chandasana ◽  
Y S Chhonker ◽  
...  
Keyword(s):  
Extended Release ◽  
Correlation Model ◽  
Development And Validation

Development of a Population Pharmacokinetics-Based in vitro-in vivo Correlation Model for Drugs with Site-Dependent Absorption: the Acyclovir Case Study

2020 ◽  
Vol 22 (2) ◽  
Author(s):  
Soyoung Shin ◽  
Tae Hwan Kim ◽  
Da Young Lee ◽  
Seung Eun Chung ◽  
Jong Bong Lee ◽  
...  
Keyword(s):  
Population Pharmacokinetics ◽  
Correlation Model ◽  
Dependent Absorption

scholarly journals Ruminal fermentation and digestion of cattle diets with total and partial replacement of soybean meal by a slow-release urea product

2019 ◽  
Vol 64 (No. 7) ◽  
pp. 294-301
Author(s):  
S Gonzalez-Munoz ◽  
J Sanchez ◽  
S Lopez-Aguirre ◽  
J Vicente ◽  
J Pinos-Rodriguez
Keyword(s):  
Soybean Meal ◽  
Degradation Rate ◽  
Slow Release ◽  
In Vitro Assay ◽  
Partial Replacement ◽  
Vitro Assay ◽  
Dietary Substitution ◽  
Slow Release Urea

One in vitro assay and one in vivo trial with ruminally cannulated Holstein steers were conducted to evaluate the effects of a dietary substitution of soybean meal by a urea and slow-release urea source of fermentation and degradation of diets for cattle. The experimental diets consisted of the total mixed rations defined as the control with soybean meal (SBM), U (urea), SRU (slow-release urea), and SRU+U+AA (0.42% + 0.42% + 1% amino acids methionine and lysine). The dietary substitution of SBM by U or SRU reduced (P < 0.05) the total gas production (V), microbial mass and degradation at 72 h incubation under the in vitro conditions, as well as the degradation rate (c) and the total volatile fatty acids (VFA) in the rumen of the steers; however, when the dietary substitution of SBM was by U+SRU+AA, those values did not decrease. In the steers, the dietary substitution of SBM by U and SRU reduced the ruminal degradation rate and the total VFA, and increased the ammonia N, but when SBM was substituted by U+SRU+AA in the diets, these changes were not observed. No advantage of SRU over U was found. The dietary substitution of SBM by U, SRU, U+SRU+AA did not modify the molar proportion of the VFA in the rumen nor were there changes in the nutrient digestion or excretion. Both the in vitro assay and the in vivo trial indicated that replacing SBM with U or SRU increases the ruminal ammonia N concentrations and reduces the degradation rate in the rumen, although those undesirable findings were not found when the SBM was replaced by U+SRU+AA. Therefore, it is feasible to replace the SBM with a combination of urea, slow-release urea, lysine and methionine in the diet for the ruminants.

Population In Vitro-In Vivo Correlation Model Linking Gastrointestinal Transit Time, pH, and Pharmacokinetics: Itraconazole as a Model Drug

2016 ◽  
Vol 33 (7) ◽  
pp. 1782-1794 ◽  
Author(s):  
Ahmad Y. Abuhelwa ◽  
Stuart Mudge ◽  
David Hayes ◽  
Richard N. Upton ◽  
David J. R. Foster
Keyword(s):  
Transit Time ◽  
Gastrointestinal Transit ◽  
Correlation Model ◽  
Gastrointestinal Transit Time ◽  
Model Drug

Improved Biopharmaceutical Properties of Oral Formulations of 1,2,4-Thiadiazole Derivative with Cyclodextrins: in Vitro and in Vivo Evaluation

2018 ◽  
Vol 4 (2) ◽  
pp. 491-501 ◽  
Author(s):  
Maria Promzeleva ◽  
Tatyana Volkova ◽  
Alexey Proshin ◽  
Oleg Siluykov ◽  
Anton Mazur ◽  
...  
Keyword(s):  
In Vivo Evaluation ◽  
Oral Formulations ◽  
Thiadiazole Derivative ◽  
Biopharmaceutical Properties

Calcium alginate beads as a slow-release system for delivering angiogenic molecules In Vivo and In Vitro

1992 ◽  
Vol 152 (2) ◽  
pp. 422-429 ◽  
Author(s):  
Elizabeth C. Downs ◽  
Nancy E. Robertson ◽  
Terry L. Riss ◽  
Marian L. Plunkett
Keyword(s):  
Calcium Alginate ◽  
Slow Release ◽  
Alginate Beads ◽  
Calcium Alginate Beads ◽  
Release System ◽  
Slow Release System

scholarly journals Silicone-Acyclovir Controlled Release Devices Suppress Primary Herpes Simplex Virus-2 and Varicella Zoster Virus InfectionsIn Vitro

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Carol L. Berkower ◽  
Nicole M. Johnson ◽  
Stephen B. Longdo ◽  
Shenika O. McGusty-Robinson ◽  
Samantha L. Semenkow ◽  
...  
Keyword(s):  
Slow Release ◽  
Clinical Symptoms ◽  
Drug Regimen ◽  
Daily Basis ◽  
Varicella Zoster ◽  
Simplex Virus ◽  
Hsv 1

Following initial infection, herpesviruses retreat into a permanent latent state with periodic reactivation resulting in an enhanced likelihood of transmission and clinical disease. The nucleoside analogue acyclovir reduces clinical symptoms of the three human alpha herpesviruses, HSV-1, HSV-2, and VZV. Long-term administration of acyclovir (ACV) can reduce the frequency and severity of reactivation, but its low bioavailability and short half-life require a daily drug regimen. Our lab is working to develop a subcutaneous delivery system to provide long-lasting, sustained release of ACV. Previously, we demonstrated that an implantable silicone (MED-4050) device, impregnated with ACV protected against HSV-1 bothin vitroandin vivo. Here, we extend ourin vitroobservations to include protection against both HSV-2 and VZV. We also demonstrate protection against HSV-2in vitrousing MED-4750, a silicone polymer designed for long-term use in humans. When release of ACV from MED-4750 is quantitated on a daily basis, an initial burst of 5 days is observed, followed by a long period of slow release with near-zero-order kinetics, with an average daily release of 1.3923 ± 0.5908 μg ACV over days 20–60. Development of a slow-release implant has the potential to significantly impact the treatment of human alpha herpesvirus infections.

VEGF165 and bFGF protein-based therapy in a slow release system to improve angiogenesis in a bioartificial dermal substitute in vitro and in vivo

2007 ◽  
Vol 392 (3) ◽  
pp. 305-314 ◽  
Author(s):  
I. Wilcke ◽  
J. A. Lohmeyer ◽  
S. Liu ◽  
A. Condurache ◽  
S. Krüger ◽  
...  
Keyword(s):  
Slow Release ◽  
Dermal Substitute ◽  
Release System ◽  
Slow Release System
Sign in / Sign up

Export Citation Format

Share Document